AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering

Published on January 6, 2025

CEO of AEON Biopharma. “We believe the capital raised in this offering is sufficient to fund operations through 2025 and will facilitate the

Continue reading on website
Other news

KRONOS CAPITAL FAMILY OF COMPANIES SET TO OPEN HEADQUARTERS IN CHATTANOOGA IN 2025

January 6, 2025
hosting equity investment negotiations with several of the world’s largest investment banks, funds, and energy investment companies. The

Qomolangma Acquisition Corp. Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

January 6, 2025
to continue to fund the extension payments persuaded us that the prudent decision was to return to stockholders the capital held in trust,